{"id":7200,"date":"2021-09-08T10:08:58","date_gmt":"2021-09-08T15:08:58","guid":{"rendered":"https:\/\/clinvest-research2021.local\/cgrp-antibodies-for-the-prevention-of-migraines\/"},"modified":"2023-06-26T15:03:49","modified_gmt":"2023-06-26T20:03:49","slug":"cgrp-antibodies-for-the-prevention-of-migraines","status":"publish","type":"post","link":"https:\/\/clinvest.com\/es\/cgrp-antibodies-for-the-prevention-of-migraines\/","title":{"rendered":"CGRP antibodies for the prevention of migraines"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Have you heard the news about the new, recently approved CGRP treatments for the prevention of Migraine? Here, we will try and cover some information about these exciting new treatment options for Migraine. <\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>Q: What are CGRP antibodies?<\/b><\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>A: <\/b><\/span><span style=\"font-weight: 400;\">This new drug class for the preventative treatment of Migraine started its development almost 10 years ago. As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP). Clinvest has been involved over the last few years in many of the clinical trials which led to approval for all three products: Aimovig<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> made by Amgen, Ajvoy<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> by Teva, and Emgality<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> by Eli Lilly. There are also several more medications in this class in the development process and on the way to approval. \u00a0<\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>Q: How do I take these medications?<\/b><\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>A: <\/b><\/span><span style=\"font-weight: 400;\">All three of the currently approved treatments are available as an injection administered subcutaneously. Aimovig<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> and Emgality<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> are typically given once a month by injection to the arm, leg or abdomen. While Ajovy<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> can be administered either monthly or quarterly. Both Aimovig<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> and Ajovy<\/span><span style=\"font-weight: 400;\">TM<\/span><span style=\"font-weight: 400;\"> had two approved doses. Many times, your first injection will be done in the doctor\u2019s office or with a nurse at home. After that, many people choose to do these injections at home without any assistance. If you want to learn more about these treatments it is best to talk with your provider. <\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>Q: What is the cost of CGRP medications and does my insurance cover them?<\/b><\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>A: <\/b><\/span><span style=\"font-weight: 400;\">While none of the new CGRP treatments are cheap and can cost almost $600 a month retail, all three of the manufacturers offer ways to receive their products at highly discounted prices. Often the discounted prices as little as $5 a month or even free. So, don\u2019t forget to ask your provider about assistance programs that might be available to reduce your cost.<\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>Q: What is the future of CGRP treatments for Migraine?<\/b><\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>A: <\/b><\/span><span style=\"font-weight: 400;\">Surprisingly, there are even more CGRP treatments on the horizon which include Alder Biopharmaceuticals, Allergan, and Biohaven. These treatments focus on different delivery systems including IV and oral administration and will hopefully get approved in the near future as well. <\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>Q: Do you want to learn more about CGRP antibodies for the prevention of migraine? <\/b><\/span><\/p>\n<p><span style=\"color: #9e1f63;\"><b>A: <\/b><\/span><span style=\"font-weight: 400;\">We are very excited to be able to provide these treatments for patients at Headache Management of Springfield and are taking new patient appointments with quick availability. \u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Give us a call today to schedule an appointment with Certified Headache Specialist, Dr. Carol Matthews, DNP to talk about treatment options. <strong>417-883-7889<\/strong><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Have you heard the news about the new, recently approved CGRP treatments for the prevention of Migraine? Here, we will try and cover some information about these exciting new treatment options for Migraine. Q: What are CGRP antibodies? A: This new drug class for the preventative treatment of Migraine started its development almost 10 years&hellip;<\/p>","protected":false},"author":1,"featured_media":7381,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-7200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CGRP antibodies for the prevention of migraines - Clinvest Research<\/title>\n<meta name=\"description\" content=\"As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinvest.com\/es\/cgrp-antibodies-for-the-prevention-of-migraines\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CGRP antibodies for the prevention of migraines - Clinvest Research\" \/>\n<meta property=\"og:description\" content=\"As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinvest.com\/es\/cgrp-antibodies-for-the-prevention-of-migraines\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinvest Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ClinvestResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T15:08:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-26T20:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/09\/antibodies.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"frankandmaven\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Clinvest417\" \/>\n<meta name=\"twitter:site\" content=\"@Clinvest417\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"frankandmaven\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/\"},\"author\":{\"name\":\"frankandmaven\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/#\\\/schema\\\/person\\\/2212291c701cc5bea6397518631c3993\"},\"headline\":\"CGRP antibodies for the prevention of migraines\",\"datePublished\":\"2021-09-08T15:08:58+00:00\",\"dateModified\":\"2023-06-26T20:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/\"},\"wordCount\":462,\"publisher\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinvest.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/antibodies.jpg\",\"articleSection\":[\"Medical News\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/\",\"url\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/\",\"name\":\"CGRP antibodies for the prevention of migraines - Clinvest Research\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinvest.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/antibodies.jpg\",\"datePublished\":\"2021-09-08T15:08:58+00:00\",\"dateModified\":\"2023-06-26T20:03:49+00:00\",\"description\":\"As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clinvest.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/antibodies.jpg\",\"contentUrl\":\"https:\\\/\\\/clinvest.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/antibodies.jpg\",\"width\":800,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/cgrp-antibodies-for-the-prevention-of-migraines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clinvest.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CGRP antibodies for the prevention of migraines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/#website\",\"url\":\"https:\\\/\\\/clinvest.com\\\/\",\"name\":\"Clinvest Research\",\"description\":\"Clinical Research in Springfield, MO\",\"publisher\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinvest.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/#organization\",\"name\":\"Clinvest Research\",\"url\":\"https:\\\/\\\/clinvest.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clinvest.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/clinvest_plain_logo.png\",\"contentUrl\":\"https:\\\/\\\/clinvest.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/clinvest_plain_logo.png\",\"width\":956,\"height\":295,\"caption\":\"Clinvest Research\"},\"image\":{\"@id\":\"https:\\\/\\\/clinvest.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ClinvestResearch\\\/\",\"https:\\\/\\\/x.com\\\/Clinvest417\",\"https:\\\/\\\/www.instagram.com\\\/clinvest417\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/clinvest-research-llc.\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/clinvest.com\\\/#\\\/schema\\\/person\\\/2212291c701cc5bea6397518631c3993\",\"name\":\"frankandmaven\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc6c6cb5ae3e8839acf66ca0841d12b1256684e68a389d97dab0cb57b45674b4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc6c6cb5ae3e8839acf66ca0841d12b1256684e68a389d97dab0cb57b45674b4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc6c6cb5ae3e8839acf66ca0841d12b1256684e68a389d97dab0cb57b45674b4?s=96&d=mm&r=g\",\"caption\":\"frankandmaven\"},\"sameAs\":[\"http:\\\/\\\/clinvestresearch.flywheelsites.com\"],\"url\":\"https:\\\/\\\/clinvest.com\\\/es\\\/author\\\/frankandmaven\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CGRP antibodies for the prevention of migraines - Clinvest Research","description":"As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinvest.com\/es\/cgrp-antibodies-for-the-prevention-of-migraines\/","og_locale":"es_MX","og_type":"article","og_title":"CGRP antibodies for the prevention of migraines - Clinvest Research","og_description":"As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP)","og_url":"https:\/\/clinvest.com\/es\/cgrp-antibodies-for-the-prevention-of-migraines\/","og_site_name":"Clinvest Research","article_publisher":"https:\/\/www.facebook.com\/ClinvestResearch\/","article_published_time":"2021-09-08T15:08:58+00:00","article_modified_time":"2023-06-26T20:03:49+00:00","og_image":[{"width":800,"height":400,"url":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/09\/antibodies.jpg","type":"image\/jpeg"}],"author":"frankandmaven","twitter_card":"summary_large_image","twitter_creator":"@Clinvest417","twitter_site":"@Clinvest417","twitter_misc":{"Escrito por":"frankandmaven","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#article","isPartOf":{"@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/"},"author":{"name":"frankandmaven","@id":"https:\/\/clinvest.com\/#\/schema\/person\/2212291c701cc5bea6397518631c3993"},"headline":"CGRP antibodies for the prevention of migraines","datePublished":"2021-09-08T15:08:58+00:00","dateModified":"2023-06-26T20:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/"},"wordCount":462,"publisher":{"@id":"https:\/\/clinvest.com\/#organization"},"image":{"@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#primaryimage"},"thumbnailUrl":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/09\/antibodies.jpg","articleSection":["Medical News"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/","url":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/","name":"CGRP antibodies for the prevention of migraines - Clinvest Research","isPartOf":{"@id":"https:\/\/clinvest.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#primaryimage"},"image":{"@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#primaryimage"},"thumbnailUrl":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/09\/antibodies.jpg","datePublished":"2021-09-08T15:08:58+00:00","dateModified":"2023-06-26T20:03:49+00:00","description":"As of October 2018, three antibodies that target an inflammatory protein which can trigger migraine attacks have been approved by the FDA for the treatment of Episodic and Chronic Migraine. This protein is called Calcitonin-Gene Related Peptide (CGRP)","breadcrumb":{"@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#primaryimage","url":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/09\/antibodies.jpg","contentUrl":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/09\/antibodies.jpg","width":800,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/clinvest.com\/cgrp-antibodies-for-the-prevention-of-migraines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinvest.com\/"},{"@type":"ListItem","position":2,"name":"CGRP antibodies for the prevention of migraines"}]},{"@type":"WebSite","@id":"https:\/\/clinvest.com\/#website","url":"https:\/\/clinvest.com\/","name":"Clinvest Research","description":"Clinical Research in Springfield, MO","publisher":{"@id":"https:\/\/clinvest.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinvest.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/clinvest.com\/#organization","name":"Clinvest Research","url":"https:\/\/clinvest.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/clinvest.com\/#\/schema\/logo\/image\/","url":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/08\/clinvest_plain_logo.png","contentUrl":"https:\/\/clinvest.com\/wp-content\/uploads\/2021\/08\/clinvest_plain_logo.png","width":956,"height":295,"caption":"Clinvest Research"},"image":{"@id":"https:\/\/clinvest.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ClinvestResearch\/","https:\/\/x.com\/Clinvest417","https:\/\/www.instagram.com\/clinvest417","https:\/\/www.linkedin.com\/company\/clinvest-research-llc."]},{"@type":"Person","@id":"https:\/\/clinvest.com\/#\/schema\/person\/2212291c701cc5bea6397518631c3993","name":"frankandmaven","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/bc6c6cb5ae3e8839acf66ca0841d12b1256684e68a389d97dab0cb57b45674b4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bc6c6cb5ae3e8839acf66ca0841d12b1256684e68a389d97dab0cb57b45674b4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bc6c6cb5ae3e8839acf66ca0841d12b1256684e68a389d97dab0cb57b45674b4?s=96&d=mm&r=g","caption":"frankandmaven"},"sameAs":["http:\/\/clinvestresearch.flywheelsites.com"],"url":"https:\/\/clinvest.com\/es\/author\/frankandmaven\/"}]}},"_links":{"self":[{"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/posts\/7200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/comments?post=7200"}],"version-history":[{"count":1,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/posts\/7200\/revisions"}],"predecessor-version":[{"id":7382,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/posts\/7200\/revisions\/7382"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/media\/7381"}],"wp:attachment":[{"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/media?parent=7200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/categories?post=7200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinvest.com\/es\/wp-json\/wp\/v2\/tags?post=7200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}